martedì, 24 novembre 2020
23 Marzo 2018

FDA Approves Nilotinib for Pediatric CML

March 22, 2018 – The FDA has approved nilotinib for the first- and second-line treatment of pediatric patients aged 1 year and older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). The approval was issued based on a cohort of 69 pediatric patients with Ph+ CML-CP enrolled across 2 trials. Patients were either newly diagnosed or resistant/intolerant to prior treatment with a tyrosine kinase inhibitor. The major molecular … (leggi tutto)